Neuropsychiatry

Apathy significantly affects cognitive impairment patients, yet remains underrecognized. Discover effective assessment and treatment strategies for improved outcomes.

Half of patients with stuttering also experience anxiety, highlighting the psychiatrist’s role in care and support.

Shelly Jo Kraft, MS, PhD, lays the foundation for a new approach that emphasizes the role of comorbidities in stuttering.

Collaborating with speech pathologists and others improve care for patients who stutter.

Gerald A. Maguire, MD, details the unmet needs in stuttering at the inaugural conference.

Alto Neuroscience reveals EEG biomarkers effectively distinguish patients with schizophrenia, enhancing treatment precision and advancing psychiatric research.

Neuroplasticity enables the brain to adapt and recover after injury, emphasizing the importance of multidisciplinary rehabilitation for effective healing.

Explore the complex interplay of genetics, environment, concussion, substance abuse, and inflammation in severe mental illnesses, revealing critical insights for prevention and treatment.

Leqembi for the treatment of Alzheimer disease has been launched in Austria on August 25, 2025, and will be launched in Germany on September 1, 2025—the first launches in the EU.

New research highlights lithium's crucial role in brain health, revealing its potential to combat Alzheimer disease and enhance mental wellness.

Antidepressant treatment for late-life depression enhances cognitive functions like memory and learning, linking symptom relief to cognitive improvement.

The complexities of Huntington disease can pose challenges for diagnosis. Let's take a look at its neuropsychiatric symptoms and the need for comprehensive treatment strategies.

Biogen's zuranolone gains positive opinion for treating postpartum depression, promising rapid symptom relief and potential EU approval by 2025.

Anavex Life Sciences reveals significant cognitive and functional improvements in early Alzheimer disease patients using blarcamesine, highlighting its potential as a long-term treatment.

The FDA has cleared the IND application for MIRA Pharmaceuticals' Ketamir-2, a promising oral treatment for neuropathic pain, which has shown superior efficacy and safety in preclinical studies.

Cognition Therapeutics reveals promising phase 2 results for zervimesine in treating dementia with Lewy bodies and Alzheimer disease at AAIC 2025.

Roche unveils promising Alzheimer disease treatments and diagnostic tools, including trontinemab and the Elecsys pTau217 blood test, at the AAIC conference.

Researchers uncover a novel biomarker for major depressive disorder, linking regional homogeneity in fMRI to decreased cerebral blood flow and symptom severity.

In this CME article, learn more about the complexities of neuropsychiatric symptoms in Parkinson disease, including psychosis and cognitive impairment, and effective treatment strategies.

Explore the complex role of dopamine in schizophrenia, its impact on symptoms, and potential therapeutic advancements.

May is American Stroke Month. Here, you can find important information about recognizing the signs of the stroke to share with patients.

Combination therapy of TMS and ketamine could enhance brain perfusion and neuroplasticity.

Research reveals that IV haloperidol and ziprasidone are safe for treating delirium in patients that are critically ill, showing minimal impact on QTc intervals.

Explore effective strategies for dementia risk reduction and understand the importance of early cognitive assessments in aging adults.

In this CME article, explore the complexities of Parkinson disease, focusing on neuropsychiatric symptoms, their prevalence, and effective treatment strategies for improved patient care.